Developing biomarkers for cerebral amyloid angiopathy trials: Do potential disease phenotypes hold promise?

The Lancet Neurology

Volumn 13, Issue 6, 2014, Pages 538-540

  Charidimou, Andreas ^a   Jäger, Hans Rolf J ^a,b  

^a NATIONAL HOSPITAL FOR NEUROLOGY AND NEUROSURGERY   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; BIOLOGICAL MARKER; APOLIPOPROTEIN E2; APOLIPOPROTEIN E4;

ALZHEIMER DISEASE; BRAIN HEMORRHAGE; COGNITIVE DEFECT; GENOTYPE; HUMAN; LETTER; NEUROIMAGING; NEUROPATHOLOGY; PHENOTYPE; PRIORITY JOURNAL; SIDEROSIS; VASCULAR AMYLOIDOSIS; WHITE MATTER LESION; DISEASE ASSESSMENT; WHITE MATTER;

BIOLOGICAL MARKERS; CEREBRAL AMYLOID ANGIOPATHY; HUMANS;

EID: 84901033767     PISSN: 14744422     EISSN: 14744465     Source Type: Journal    
DOI: 10.1016/S1474-4422(14)70096-1     Document Type: Letter

References (6)

1. Greenberg SM, Salman RA, Biessels GJ, et al. Outcome markers for clinical trials in cerebral amyloid angiopathy. Lancet Neurol 2014, 13:419-428.
2. Charidimou A, Gang Q, Werring DJ Sporadic cerebral amyloid angiopathy revisited: recent insights into pathophysiology and clinical spectrum. J Neurol Neurosurg Psychiatry 2012, 83:124-137.
3. Vinters HV Cerebral amyloid angiopathy. A critical review. Stroke 1987, 18:311-324.
4. Greenberg SM, Vonsattel JP, Stakes JW, Gruber M, Finklestein SP The clinical spectrum of cerebral amyloid angiopathy: presentations without lobar hemorrhage. Neurology 1993, 43:2073-2079.
5. Greenberg SM, Nandigam RN, Delgado P, et al. Microbleeds versus macrobleeds: evidence for distinct entities. Stroke 2009, 40:2382-2386.
6. Charidimou A, Jäger RH, Fox Z, et al. Prevalence and mechanisms of cortical superficial siderosis in cerebral amyloid angiopathy. Neurology 2013, 81:626-632.